Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q86TM3 (cage)
 29,987 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Diarrheal disease associated with abortions and stillbirths occurred in a group of 42 Macaca fascicularis. The group was composed of wild-caught adults and their colony-born offspring housed in a half-acre cage. Thirteen adult females and 1 infant male were affected. All 14 monkeys had diarrhea and all 9 pregnant females either aborted or had a stillbirth. Yersinia pseudotuberculosis was isolated from 7 animals. In addition, Y enterocolitica was isolated from 1 monkey and Shigella flexneri type IV was isolated from 5 monkeys. One adult female had a mixed infection of both Y pseudotuberculosis and S flexneri. Every pregnant monkey from which Y pseudotuberculosis was isolated aborted or had a stillbirth. Five animals died, and Y pseudotuberculosis was the only pathogen isolated from these 5 monkeys.
 ...
PMID:Yersinia pseudotuberculosis infection in a group of Macaca fascicularis. 700 2

Sera from 100 patients not infected with Serratia marcescens at the time of hospital admission lacked detectable H-immobilizing antibodies against all 20 currently recognized H-antigens of this microorganism. However, various patient sera revealed elevated titers of O-agglutinins against several of the 20 O-antigens of S. marcescens, in a particular O-antigens, O1, O3, O4, O5, O7, O8, O10, O11, O16, O17, O18, O19, and O20. Rabbit anti-Shigella serogroup B immune serum cross-reacted with S. marcescens O-antigens O1 and O10; anti-Shigella serogroup C serum cross-reacted weakly with S. marcescens O-antigen O8. Conversely, rabbit anti-S. marcescens O1 and O10 immune sera cross-reacted with a clinical isolate of Shigella flexneri. None of the anti-S. marcescens O1-O20 rabbit immune sera reacted with commercial febrile antigens of Salmonella serogroups A, B, C1,2, D, E1,2,3,4, Brucella abortus, Francisella tularensis, and Proteus OX19. However, a reference strain of Salmonella typhi (9;d,-) was agglutinated by anti S. marcescens anti-O8 and O10 sera, a reference strain of S. paratyphi B (4,5;-,-) weakly by anti-S. marcescens O8 serum, and a reference strain of S. paratyphi C (6,8;-,-) by anti-S. marcescens anti-O10 and O16 rabbit immune sera. None of the anti-S. marcescens H-antisera cross-reacted with H-antigens of S. typhi (o;d,-), S. paratyphi A (1,2;a,-), S. paratyphi B (4,5;b,0), S. choleraesuis (6,7;-,1,5), typhimurium (4,5;,i,-), and S. enteritidis (9;gm,-). Yersinia enterocolitica reference strain Ye 75 (OI = O3) eas agglutinated weakly by anti-S. marcescens O2 serum, whereas Y. enterocolitica reference strain Ye 373 (OV = O9) cross-reacted with S. marcescens anti-O5 rabbit immune serum. Intravenously and tissue cage-infected rabbits developed anti-H and anti-O-antibodies within 5 to 12 days after infection with representative test strains of S. marcescens. Therefore, it is suggested that the serodiagnosis of human S. marcescens infections consist of serial monitoring of both anti-H and anti-O agglutinins, because determinations of the latter alone might yield false-positive, i.e., potentially misleading results.
 ...
PMID:Towards serodiagnosis of Serratia marcescens infections: examination of sera from noninfected patients and from experimentally infected rabbits for anti-H and anti-O antibodies; S. marcescens O-antigen cross-reactions with those of other enterobacteriaceae. 703 90

RNA interference (RNAi) represents a high effective mechanism for specific inhibition of mRNA expression. Besides its potential as a powerful laboratory tool, the RNAi pathway appears to be promising for therapeutic utilization. For development of RNA interference (RNAi)-based therapies, delivery of RNAi-mediating agents to target cells is one of the major obstacles. A novel strategy to overcome this hurdle is transkingdom RNAi (tkRNAi). This technology uses non-pathogenic bacteria, e.g. Escherichia coli, to produce and deliver therapeutic short hairpin RNA (shRNA) into target cells to induce RNAi. A first-generation tkRNAi-mediating vector, TRIP, contains the bacteriophage T7 promoter for expression regulation of a therapeutic shRNA of interest. Furthermore, TRIP has the Inv locus from Yersinia pseudotuberculosis that encodes invasin, which permits natural noninvasive bacteria to enter beta1-integrin-positive mammalian cells and the HlyA gene from Listeria monocytogenes, which produces listeriolysin O. This enzyme allows the therapeutic shRNA to escape from entry vesicles within the cytoplasm of the target cell. TRIP constructs are introduced into a competent non-pathogenic Escherichia coli strain, which encodes T7 RNA polymerase necessary for the T7 promoter-driven synthesis of shRNAs. A well-characterized cancer-associated target molecule for different RNAi strategies is ABCB1 (MDR1/P-glycoprotein, MDR1/P-gp). This ABC-transporter acts as a drug extrusion pump and mediates the "classical" ABCB1-mediated multidrug resistance (MDR) phenotype of human cancer cells which is characterized by a specific cross resistance pattern. Different ABCB1-expressing MDR cancer cells were treated with anti-ABCB1 shRNA expression vector bearing E. coli. This procedure resulted in activation of the RNAi pathways within the cancer cells and a considerable down regulation of the ABCB1 encoding mRNA as well as the corresponding drug extrusion pump. Accordingly, drug accumulation was enhanced in the pristine drug-resistant cancer cells and the MDR phenotype was reversed. By means of this model the data provide the proof-of-concept that tkRNAi is suitable for modulation of cancer-associated factors, e.g. ABCB1, in human cancer cells.
 ...
PMID:Bacterial delivery of RNAi effectors: transkingdom RNAi. 2081 23